Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. Karyopharm is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.

Employee Rating

3.1More
TypeSubsidiary
Parent CompanyBiogen
HQNewton, US
Founded2008
Websitekaryopharm.com
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Karyopharm Therapeutics

Michael Kauffman

Michael Kauffman

Chief Executive Officer &Board of Directors
John McCartney

John McCartney

Senior Director, Product Leadership
Brian Austad

Brian Austad

Vice President, Head of Pharmaceutical Sciences
Dilara McCauley

Dilara McCauley

Vice President, Product Leadership
Show more

Karyopharm Therapeutics Office Locations

Karyopharm Therapeutics has offices in Newton and München
Newton, (HQ)
85 Wells Ave
München,
9 Franziska-Bilek-Weg
Show all (2)
Report incorrect company information

Karyopharm Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2008

Total Funding

$248.7 m

Investors

Karyopharm Therapeutics is a subsidiary of Biogen

Karyopharm Therapeutics Revenue

Karyopharm Therapeutics's revenue was reported to be $250 k in FY, 2015 which is a 9.2% increase from the previous period.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

387.0k229.0k250.0k

Revenue growth, %

(41%)9%

General and administrative expense

5.9m15.9m21.6m23.9m24.9m

R&D expense

28.5m60.1m97.7m86.9m107.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

1.6m2.9m3.3m3.8m5.4m6.2m4.8m5.6m6.0m5.9m6.3m6.6m5.8m7.6m17.1m

R&D expense

7.7m11.0m13.2m16.0m20.8m27.0m25.9m21.8m24.6m19.9m24.1m23.1m25.2m41.3m86.1m

Operating expense total

9.3m13.9m16.5m19.8m26.2m33.2m30.7m27.3m30.5m25.8m30.3m29.8m31.1m48.9m103.2m

EBIT

(9.3m)(13.7m)(16.4m)(19.7m)(26.1m)(33.0m)(30.6m)(27.3m)(30.5m)(25.7m)(30.3m)(29.8m)(31.1m)(38.9m)(73.3m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

156.0m150.6m58.4m49.7m69.0m

Accounts Receivable

Inventories

2.0m2.0m2.0m2.1m

Current Assets

158.0m207.8m177.6m131.6m148.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

52.9m144.9m132.3m227.1m51.5m24.2m43.5m42.2m37.7m43.9m25.6m55.4m54.5m37.5m119.0m

Current Assets

53.6m147.6m135.3m231.3m249.3m225.3m198.3m138.1m124.2m130.3m112.2m145.7m121.7m133.3m244.6m

PP&E

246.0k322.0k604.0k2.7m3.3m3.2m3.7m3.3m3.2m3.0m2.7m2.5m2.3m2.5m2.6m

Total Assets

55.9m149.3m137.7m235.2m292.0m263.3m237.0m192.1m170.9m183.6m155.4m185.8m163.8m146.4m256.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(33.9m)(75.8m)(118.2m)(109.6m)(129.0m)

Depreciation and Amortization

144.0k323.0k634.0k717.0k713.0k

Inventories

(1.4m)(45.0k)(55.0k)(120.0k)

Accounts Payable

664.0k4.5m(2.4m)945.0k909.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(21.8m)(13.7m)(30.1m)(49.8m)(26.1m)(58.8m)(30.4m)(27.1m)(30.2m)(82.6m)(29.9m)(59.3m)(89.9m)(38.5m)(72.1m)

Depreciation and Amortization

106.0k85.0k191.0k292.0k537.0k363.0k539.0k169.0k353.0k

Accounts Payable

673.0k1.7m362.0k7.0m(1.8m)4.6m4.1m4.1m(1.7m)4.2m(1.5m)(2.9m)(773.0k)(1.9m)

Cash From Operating Activities

(20.2m)(22.5m)(38.7m)(48.3m)(64.4m)(46.4m)(68.2m)(34.7m)(72.3m)
Show all financial metrics

Karyopharm Therapeutics Operating Metrics

FY, 2015

Patents Issued

10
Show all operating metrics
Report incorrect company information

Karyopharm Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Karyopharm Therapeutics News and Updates

Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers’ Option

NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “notes”) pursuant to t…

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 196,500 shares of Karyopharm’s …
Report incorrect company information

Karyopharm Therapeutics Blogs

Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes

Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes Content Import Thu, 10/11/2018 - 07:03 Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes Oct 11, 2018 This release is a backfill from a Ne…

Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes

Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes Content Import Tue, 10/09/2018 - 16:03 Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes Oct 9, 2018 T…

Selinexor Clinical Data to be Presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology

-- Two Oral Presentations Highlighting Previously Reported Phase 2b STORM Data in Patients with Penta-Refractory Multiple Myeloma and Phase 2b SADAL Data in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma -- -- One Poster Presentation Featuring Previously Reported Phase 1b/2

Ian Karp

Ian Karp Brian.Hoenig@n… Tue, 09/18/2018 - 12:54 Ian Karp Vice President, Investor and Public Relations Ian is responsible for leading Karyopharm’s corporate communications activities, including corporate visibility, financial communicat…

Karyopharm Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma

--     Company to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Recent Business Developments on Tuesday, August 7, 2018 at 8:30 a.m. ET --  NEWTON, Mass. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical

Karyopharm Appoints Ian Karp as Vice President, Investor and Public Relations

--  Formerly of Shire, MedImmune, Centocor and Pharmacia; Brings Over 20 Years of Healthcare Industry Leadership Experience --  NEWTON, Mass. , July 25, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of
Show more

Karyopharm Therapeutics Company Life and Culture

Report incorrect company information

Karyopharm Therapeutics Frequently Asked Questions

  • When was Karyopharm Therapeutics founded?

    Karyopharm Therapeutics was founded in 2008.

  • Who are Karyopharm Therapeutics key executives?

    Karyopharm Therapeutics's key executives are Michael Kauffman, John McCartney and Brian Austad.

  • Who are Karyopharm Therapeutics competitors?

    Competitors of Karyopharm Therapeutics include Pharmacyclics, Stemline Therapeutics and Cascadian Therapeutics.

  • Where is Karyopharm Therapeutics headquarters?

    Karyopharm Therapeutics headquarters is located at 85 Wells Ave, Newton.

  • Where are Karyopharm Therapeutics offices?

    Karyopharm Therapeutics has offices in Newton and München.

  • How many offices does Karyopharm Therapeutics have?

    Karyopharm Therapeutics has 2 offices.